



The pig as a model for therapeutic human anti-cancer vaccine development, elucidating the T-cell reactivity against IDO and RhoC

Overgaard, Nana Haahr; Frøsig, Thomas Mørch; Welner, Simon; Rasmussen, Michael; Ilsøe, Mette; Sørensen, Maria Rathmann; Andersen, Mads Hald; Buus, Søren; Jungersen, Gregers

Publication date:
2015

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Overgaard, N. H., Frøsig, T. M., Welner, S., Rasmussen, M., Ilsøe, M., Sørensen, M. R., Andersen, M. H., Buus, S., & Jungersen, G. (2015). *The pig as a model for therapeutic human anti-cancer vaccine development, elucidating the T-cell reactivity against IDO and RhoC*. Abstract from 5th European Veterinary Immunology Workshop, Vienna, Austria.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

The pig as a model for therapeutic human anti-cancer vaccine development, elucidating the T-cell reactivity against IDO and RhoC

Nana Haahr Overgaard¹, Thomas Mørch Frøsig¹, Simon Welner¹, Michael Rasmussen², Mette Ilsøe¹, Maria Rathmann Sørensen¹, Mads Hald Andersen³, Søren Buus² and Gregers Jungersen¹

¹National Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark. ²Department of International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen N, Denmark. ³Center for Cancer Immune Therapy, Department of Hematology, Copenhagen University Hospital, Herlev, Denmark.

Immunotherapy against cancer has shown increased overall survival of metastatic cancer patients and is a promising new vaccine target. For this to succeed, appropriate tailoring of vaccine formulations to mount *in vivo* cytotoxic T cell (CTL) responses towards co-delivered cancer antigens is important. Previous development of therapeutic cancer vaccines has largely been based on studies in mice and the majority of these candidate vaccines failed to establish therapeutic responses in subsequent human clinical trials. Since the porcine immunome is more closely related to the human counterpart, we here introduce pigs as a superior large animal model for human cancer vaccine development via the use of our unique technology for swine leukocyte antigen (SLA) production. IDO and RhoC, both known to be important in human cancer development and progression, were used as vaccine targets. Pigs were immunized with overlapping 20-mer peptides spanning the entire porcine IDO and RhoC sequences formulated in a panel of CTL-inducing adjuvants. 198 candidate IDO- and RhoC-derived 9-11mer peptides potentially binding to SLA-1*04:01, -1*07:02, -2*04:01, -2*05:02 and/or -3*04:01 were identified *in silico*, and peptide-SLA complex stability measurements revealed 89 stable ($t_{1/2} \geq 0.5$ hour) complexes. Vaccine-induced peptide-specific CTL responses were monitored using IFN- γ release as a read out. We found responses to IDO- and RhoC-derived peptides across all groups; surprisingly non-stably binding peptides also induced responses. None of the adjuvants was found to be superior as they were all capable of generating CTL responses to IDO and RhoC hence supporting the further use of pigs as a large animal model for vaccine development against human cancer.